{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:45:14Z","timestamp":1777481114989,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cannabis &amp; Cannabinoid Research"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>There is a growing body of literature supporting the efficacy of cannabis-based medicinal products (CBMPs). Despite an increase in prescribing globally, there is a paucity of high-quality clinical data on the efficacy of CBMPs for many conditions. This study aims to detail the changes in health-related quality of life (HRQoL) and associated clinical safety in patients prescribed CBMPs for any clinical indication from the UK Medical Cannabis Registry (UKMCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      An uncontrolled prospective case series of the UKMCR was analyzed. Primary outcomes included change from baseline in patient-reported outcome measures collected across all patients (the Generalized Anxiety Disorder Scale [GAD-7], EQ-5D-5L, and Sleep Quality Scale [SQS]) at 1, 3, and 6 months. Secondary outcomes included the self-reported incidence and severity of adverse events. Statistical significance was defined as\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.050.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Three hundred twelve patients were included in the final analysis, with a mean age of 44.8. The most common primary diagnoses were chronic pain of undefined etiology (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =102, 32.7%), neuropathic pain (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =43, 13.8%), and fibromyalgia (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =31, 9.9%). Before enrolment, 112 (35.9%) patients consumed cannabis daily. The median cannabidiol and (\u2212)-trans-\u0394\n                      <jats:sup>9<\/jats:sup>\n                      -tetrahydrocannabinol doses prescribed at baseline were 20.0\u2009mg (0.0\u2013510.0\u2009mg) and 3.0\u2009mg (0.0\u2013660.0\u2009mg), respectively. Statistically significant improvements were observed in GAD-7, EQ-5D-5L Index, EQ-5D Visual Analog Scale and SQS scores at 1, 3, and 6 months (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.050). There were 94 (30.1%) reported adverse events, of which nausea (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =12, 3.8%), dry mouth (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =10, 3.2%), dizziness (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =7, 2.2%), and somnolence (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =7, 2.2%) were the most common.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study demonstrated CBMP treatment to be associated with a relatively low incidence of severe adverse events in the medium-term. Positive changes following treatment were observed in general, as well as anxiety and sleep-specific, HRQoL outcomes. Randomized controlled trials are still awaited to assess causation; however, real-world evidence can help inform current clinical practice, future trials, and is an important component of pharmacovigilance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/can.2021.0145","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T14:55:35Z","timestamp":1643036135000},"page":"557-566","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-313X","authenticated-orcid":false,"given":"Mehmet","family":"Ergisi","sequence":"first","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-6501","authenticated-orcid":false,"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."},{"name":"Sapphire Medical Clinics, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Harris","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kawka","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devaki","family":"Nimalan","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Salazar","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Loupasaki","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayyan","family":"Ali","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Holvey","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics, London, United Kingdom."},{"name":"St. George's Hospital NHS Trust, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azfer","family":"Usmani","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics, London, United Kingdom."},{"name":"Dartford and Gravesham NHS Trust, Kent, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Sajad","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics, London, United Kingdom."},{"name":"Dudley Group of Hospitals NHS Trust, West Midlands, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil","family":"Beri","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."},{"name":"Sapphire Medical Clinics, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Hoare","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."},{"name":"Sapphire Medical Clinics, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaheen A.","family":"Khan","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics, London, United Kingdom."},{"name":"Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Weatherall","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics, London, United Kingdom."},{"name":"Buckinghamshire Healthcare NHS Trust, Amersham, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Platt","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."},{"name":"Sapphire Medical Clinics, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics, London, United Kingdom."},{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, United Kingdom."},{"name":"South London and Maudsley NHS Foundation Trust, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, United Kingdom."},{"name":"Sapphire Medical Clinics, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"e_1_3_7_2_2","unstructured":"Aguilar S Guti\u00e9rrez V S\u00e1nchez L Nougier M. Medicinal cannabis policies and practices around the world. International Drug Policy Consortium. 2018. Available at https:\/\/idpc.net\/publications\/2018\/04\/medicinal-cannabis-policies-and-practices-around-the-world (Accessed April17 2021)."},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1141"},{"key":"e_1_3_7_4_2","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Medical use of cannabis and cannabinoids: questions and answers for policymaking. 2018. Available at https:\/\/www.emcdda.europa.eu\/publications\/rapid-communications\/medical-use-of-cannabis-and-cannabinoids-questions-and-answers-for-policymaking_en (Accessed April17 2021)."},{"key":"e_1_3_7_5_2","unstructured":"UK Government. The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England Wales and Scotland) Regulations 2018. Available at https:\/\/www.legislation.gov.uk\/uksi\/2018\/1055\/made (Accessed April17 2021)."},{"key":"e_1_3_7_6_2","first-page":"CD012182","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke M","year":"2018","unstructured":"M\u00fccke M, , Phillips T, , Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018; 3:CD012182.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6358"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2409-8"},{"key":"e_1_3_7_9_2","unstructured":"UK Government. Rescheduling of cannabis-based products for medicinal use in humans. 2018. Available at https:\/\/www.gov.uk\/government\/publications\/circular-0182018-rescheduling-of-cannabis-based-products-for-medicinal-use-in-humans\/rescheduling-of-cannabis-based-products-for-medicinal-use-in-humans-accessible-version (Accessed April17 2021)."},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12570"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1039\/C6NP00074F"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2019.06.005"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.5740\/jaoacint.18-0208"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030833"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.09.005"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112460109"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976193300"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.184"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12183"},{"key":"e_1_3_7_20_2","author":"Sakal C","year":"2021","unstructured":"Sakal C, , Lynskey M, , Schlag AK, et al. Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. Psychopharmacology (Berl). 2021.","journal-title":"Psychopharmacology (Berl)"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_7_22_2","unstructured":"Medicines and Healthcare products Regulatory Agency. The supply of unlicensed cannabis-based products for medicinal use in humans. 2020. Available at https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/869284\/Cannabis_Guidance__unlicensed_CBPMs__updated_2020.pdf Accessed June1 2021."},{"key":"e_1_3_7_23_2","unstructured":"World Health Organization. Integrating palliative care and symptom relief into primary health care: a WHO guide for planners implementers and managers. 2018. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/274559 Accessed June1 2021."},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.3414\/ME17-01-0051"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.626853"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-021-00078-w"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/medlaw\/fwaa002"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101010"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.01.019"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30401-8"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110379283"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.6"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.091414"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000435"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab149"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1961"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S115014"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1782"}],"container-title":["Cannabis &amp; Cannabinoid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/can.2021.0145","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2021.0145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2021.0145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:40Z","timestamp":1777385500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/can.2021.0145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5,1]]}},"alternative-id":["10.1089\/can.2021.0145"],"URL":"https:\/\/doi.org\/10.1089\/can.2021.0145","relation":{},"ISSN":["2578-5125","2378-8763"],"issn-type":[{"value":"2578-5125","type":"print"},{"value":"2378-8763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}